검색어 : 통합검색[Patel Nitin R.]
총 182건 중 182건 출력
, 19/19 페이지
-
181
- Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
- Jain, Nitin; Keating, Michael J.; Thompson, Philip A.; Burger, Jan A.; Ferrajoli, Alessandra; Estrov, Zeev E.; Borthakur, Gautam M.; Takahashi, Koichi; Bose, Prithviraj; Fowler, Nathan H.; Kadia, Tapan M.; Daver, Naval G.; Konopleva, Marina Y; Alvarado, Yesid; Yilmaz, Musa; DiNardo, Courtney D.; Ohanian, Maro; Pemmaraju, Naveen; Jabbour, Elias; Sasaki, Koji; Kanagal-Shamanna, Rashmi; Patel, Keyur; Jorgensen, Jeffrey L.; Wang, Sa A; Garg, Naveen; Wang, Xuemei; Sondermann, Katrina; Cruz, Nichole; Wei, Chongjuan; Ayala, Ana; Plunkett, William; Kantarjian, Hagop M.; Gandhi, Varsha; Wierda, William G.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center, Houston, TX; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; M.D. Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas; (Blood, v.134, 2019, pp.359-359)
-
182
- Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial
- Sidiqi, M Hasib; Corradini, Paolo; Purtill, Duncan; Einsele, Hermann; Dhakal, Binod; Karlin, Lionel; Manier, Salomon; Iida, Shinsuke; Giebel, Sebastian; Harrison, Simon J.; Lipe, Brea; Khan, Abdullah; Schecter, Jordan M.; Jackson, Carolyn Chang; Yeh, Tzu-min; Banerjee, Arnob; Deraedt, William; Lendvai, Nikoletta; Lonardi, Carolina; Slaughter, Ana; Li, Katherine; Chen, Diana; Gilbert, Jane; Roccia, Tito; Zhao, Man; Patel, Nitin; Florendo, Erika; Koneru, Mythili; Costa Filho, Octavio; Geng, Dong; San Miguel, Jesus; Yong, Kwee; 1Fiona Stanley Hospital, Perth, Australia; 3University of Milan, Milan, Italy; 4Haematology Department, Fiona Stanley Hospital, Perth, Australia; 5Universitä tsklinikum Wü rzburg, Medizinische Klinik und Poliklinik II, Wü rzburg, Germany; 6Medical College of Wisconsin, Milwaukee, WI; 7Centre Hospitalier Lyon Sud, Pierre-Bé nite, France; 8University of Lille, Lille, France; 9Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan; 10Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland; 12Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; 15University of Rochester Medical Center, Rochester, NY; 16The Ohio State University Comprehensive Cancer Center, Columbus, OH; 17Janssen Research & Development, Raritan, NJ; 17Janssen Research & Development, R; (Blood, v.142, 2023, pp.4866-4866)
QUICK MENU
